JP2014519516A5 - - Google Patents

Download PDF

Info

Publication number
JP2014519516A5
JP2014519516A5 JP2014514911A JP2014514911A JP2014519516A5 JP 2014519516 A5 JP2014519516 A5 JP 2014519516A5 JP 2014514911 A JP2014514911 A JP 2014514911A JP 2014514911 A JP2014514911 A JP 2014514911A JP 2014519516 A5 JP2014519516 A5 JP 2014519516A5
Authority
JP
Japan
Prior art keywords
covalently attached
ribonucleotides
positions
pharmaceutical composition
moiety covalently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519516A (ja
JP5873168B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041761 external-priority patent/WO2012170957A2/en
Publication of JP2014519516A publication Critical patent/JP2014519516A/ja
Publication of JP2014519516A5 publication Critical patent/JP2014519516A5/ja
Application granted granted Critical
Publication of JP5873168B2 publication Critical patent/JP5873168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514911A 2011-06-08 2012-06-08 Ｈｓｐ４７発現の調節を増強するレチノイド−リポソーム Active JP5873168B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161494832P 2011-06-08 2011-06-08
US61/494,832 2011-06-08
US201161497447P 2011-06-15 2011-06-15
US61/497,447 2011-06-15
PCT/US2012/041761 WO2012170957A2 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression

Publications (3)

Publication Number Publication Date
JP2014519516A JP2014519516A (ja) 2014-08-14
JP2014519516A5 true JP2014519516A5 (enExample) 2015-07-23
JP5873168B2 JP5873168B2 (ja) 2016-03-01

Family

ID=46395700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514911A Active JP5873168B2 (ja) 2011-06-08 2012-06-08 Ｈｓｐ４７発現の調節を増強するレチノイド−リポソーム

Country Status (21)

Country Link
US (4) US8741867B2 (enExample)
EP (2) EP2717921B1 (enExample)
JP (1) JP5873168B2 (enExample)
KR (1) KR102002771B1 (enExample)
CN (1) CN103781909B (enExample)
AU (1) AU2012267472B2 (enExample)
CA (1) CA2836925C (enExample)
CY (2) CY1117683T1 (enExample)
DK (2) DK2717921T3 (enExample)
ES (2) ES2689696T3 (enExample)
HR (1) HRP20181440T8 (enExample)
HU (1) HUE039379T2 (enExample)
LT (1) LT3075855T (enExample)
PL (2) PL2717921T3 (enExample)
PT (2) PT3075855T (enExample)
RS (1) RS57824B1 (enExample)
RU (1) RU2628694C2 (enExample)
SI (1) SI3075855T1 (enExample)
SM (1) SMT201800584T1 (enExample)
TW (1) TWI658830B (enExample)
WO (1) WO2012170957A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20160038593A1 (en) * 2004-12-22 2016-02-11 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
WO2011072082A2 (en) * 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
US10196637B2 (en) * 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
AU2012267467B8 (en) * 2011-06-08 2017-06-15 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
IN2014MN00908A (enExample) * 2011-11-18 2015-04-17 Nitto Denko Corp
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
WO2015135138A1 (en) * 2014-03-11 2015-09-17 Yi-Wen Wang Pharmaceutical composition and method for reducing scar formation
CN104174034A (zh) * 2014-08-20 2014-12-03 南京大学 肝星状细胞靶向的基因药物输送载体及其制备方法和应用
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
CN108367022A (zh) 2015-12-13 2018-08-03 日东电工株式会社 具有高活性和降低脱靶的sirna结构
EP3458032A4 (en) 2016-05-16 2019-12-25 The Board of Regents of The University of Texas System CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11771703B2 (en) * 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
US20200318113A1 (en) * 2019-03-05 2020-10-08 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof
TWI740533B (zh) 2020-06-11 2021-09-21 國立中央大學 評估個體罹患腹膜硬化症之風險的方法、其分析器及其套組
KR20230042279A (ko) * 2020-06-24 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 표적화 분자의 합성 방법
CN116437904A (zh) * 2020-08-25 2023-07-14 劳伦制药公司 芬维a胺或其类似物用于治疗肺纤维化的用途
CN118922182A (zh) * 2022-02-04 2024-11-08 纽约大学 类维生素a治疗心房颤动的用途
EP4504231A1 (en) 2022-04-08 2025-02-12 University of North Texas Health Science Center at Fort Worth Treatment for ocular fibrosis
WO2024059714A1 (en) * 2022-09-15 2024-03-21 Bristol-Myers Squibb Company Method of treating advanced hepatic fibrosis associated with hcv infection with targeted lipid nanoparticle compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
PT88550A (pt) 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
EP1044987B1 (en) 1991-12-24 2006-02-15 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO1995028493A1 (en) 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19640092A1 (de) 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
KR100573231B1 (ko) 1999-02-12 2006-04-24 상꾜 가부시키가이샤 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE10012151A1 (de) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
ES2284959T3 (es) 2001-10-30 2007-11-16 Nektar Therapeutics Al, Corporation Conjugados polimericos solubles en agua de acido retinoico.
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
EP2141234B1 (en) 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Short Interfering RNA (siRNA) Analogues
JP2006522140A (ja) 2003-03-31 2006-09-28 ベクトラメッド，インコーポレーテッド 線維症の治療用ポリマー薬剤
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP4005601A1 (en) * 2004-12-22 2022-06-01 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
JP5704741B2 (ja) * 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
DE202006005347U1 (de) * 2006-04-03 2007-08-02 Efbe Elektrogeräte GmbH Infrarotleuchte
EP2076600A1 (en) 2006-10-18 2009-07-08 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
JP2010527914A (ja) 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
EP2207570A2 (en) * 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US20100028416A1 (en) 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
AR073582A1 (es) 2008-09-12 2010-11-17 Nitto Denko Corp Agentes de produccion de imagenes de enfermedades fibroticas.conjugado. metodo
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
WO2011072082A2 (en) * 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
AU2011261434B2 (en) * 2010-06-02 2015-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體

Similar Documents

Publication Publication Date Title
JP2014519516A5 (enExample)
US12344841B2 (en) Chimeric double-stranded nucleic acid
RU2013158469A (ru) Липосомы с ретиноидом для усиления модуляции экспрессии hsp47
Quijano et al. Therapeutic peptide nucleic acids: principles, limitations, and opportunities
Shu et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy
CA2917320C (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease
Lu et al. Providing oligonucleotides with steric selectivity by brush-polymer-assisted compaction
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
JP5795072B2 (ja) Ｒｎａ干渉を誘導する核酸分子及びその用途
RU2487716C2 (ru) Новые структуры малых интерферирующих рнк (sirna)
Jirka et al. Peptide conjugation of 2′-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice
ES2984979T3 (es) Oligo ARN de doble cadena y composición farmacéutica que comprende el mismo para la prevención o tratamiento de fibrosis o enfermedades respiratorias
JP2014518612A5 (enExample)
JP2015519047A5 (enExample)
JP2009544281A5 (enExample)
JP2014509511A5 (enExample)
JP2018519835A5 (enExample)
JP2012530715A5 (enExample)
JP2013532952A5 (enExample)
JP2017516461A (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
CA3089396A1 (en) Nanoparticle-hydrogel composite for nucleic acid molecule delivery
JP2020518552A5 (enExample)
RU2009106071A (ru) Средства ингибирования экспрессии протеинкиназы 3
JP2014508161A5 (enExample)
US20210139893A1 (en) G-quadruplex-containing antisense oligonucleotides